Lavipharm S.A
Lavipharm S.A. engages in the research, development, manufacturing, import, marketing, sale, and wholesaling of pharmaceutical, dermocosmetic, and healthcare products in Greece and internationally. The company offers pharmaceutical products for cardiology, chronic pain and oncology, central nervous system, respiratory system, gastrointestinal system, and urology; and over the counter (OTC) drugs,… Read more
Lavipharm S.A (LAVI) - Total Assets
Latest total assets as of December 2024: €125.48 Million EUR
Based on the latest financial reports, Lavipharm S.A (LAVI) holds total assets worth €125.48 Million EUR as of December 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Lavipharm S.A - Total Assets Trend (2014–2024)
This chart illustrates how Lavipharm S.A’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Lavipharm S.A - Asset Composition Analysis
Current Asset Composition (December 2024)
Lavipharm S.A's total assets of €125.48 Million consist of 35.9% current assets and 64.1% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 4.5% |
| Accounts Receivable | €15.61 Million | 12.4% |
| Inventory | €19.46 Million | 15.5% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €49.68 Million | 39.6% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2014–2024)
This chart illustrates how Lavipharm S.A's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Lavipharm S.A's current assets represent 35.9% of total assets in 2024, an increase from 23.6% in 2014.
- Cash Position: Cash and equivalents constituted 4.5% of total assets in 2024, up from 2.9% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 39.0% of total assets, an increase from 11.0% in 2014.
- Asset Diversification: The largest asset category is intangible assets at 39.6% of total assets.
Lavipharm S.A Competitors by Total Assets
Key competitors of Lavipharm S.A based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Medicon Hellas S.A.
AT:MEDIC
|
Greece | €31.81 Million |
|
Tsumura & Co
MU:TSUA
|
Germany | €516.49 Billion |
|
Admie Holding S.A
AT:ADMIE
|
Greece | €4.65 Billion |
|
Akritas S.A
AT:AKRIT
|
Greece | €52.19 Million |
|
Alumil Aluminium Industry S.A
AT:ALMY
|
Greece | €516.26 Million |
|
Alpha Services and Holdings S.A.
AT:ALPHA
|
Greece | €73.48 Billion |
|
Alpha Trust Andromeda Investment Trust S.A
AT:ANDRO
|
Greece | €36.66 Million |
|
As Commercial Industrial Company of Computers and Toys S.A.
AT:ASCO
|
Greece | €36.47 Million |
Lavipharm S.A - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Lavipharm S.A generates 0.42x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Solid ROA - For every $100 in assets, Lavipharm S.A generates $7.16 in net profit.
Lavipharm S.A - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.15 | 1.28 | 1.21 |
| Quick Ratio | 0.65 | 0.86 | 0.87 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €5.88 Million | € 9.85 Million | € 3.73 Million |
Lavipharm S.A - Advanced Valuation Insights
This section examines the relationship between Lavipharm S.A's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.58 |
| Latest Market Cap to Assets Ratio | 0.64 |
| Asset Growth Rate (YoY) | 9.3% |
| Total Assets | €125.48 Million |
| Market Capitalization | $80.56 Million USD |
Valuation Analysis
Below Book Valuation: The market values Lavipharm S.A's assets below their book value (0.64 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Lavipharm S.A's assets grew by 9.3% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Lavipharm S.A (2014–2024)
The table below shows the annual total assets of Lavipharm S.A from 2014 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €125.48 Million | +9.32% |
| 2023-12-31 | €114.79 Million | +0.54% |
| 2022-12-31 | €114.17 Million | +116.47% |
| 2021-12-31 | €52.74 Million | +4.15% |
| 2020-12-31 | €50.64 Million | +2.46% |
| 2019-12-31 | €49.42 Million | +17.96% |
| 2018-12-31 | €41.90 Million | -6.50% |
| 2017-12-31 | €44.81 Million | -6.99% |
| 2016-12-31 | €48.18 Million | -41.52% |
| 2015-12-31 | €82.38 Million | -1.72% |
| 2014-12-31 | €83.82 Million | -- |